Lacrymed

Quick links to important sections

Lacrymed

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lacrymed

Quick Facts

Property Description
Active ingredient Povidone Iodine (PVP-I)
Form Ophthalmic Solution (Aqueous)
Pharmacological class Iodophor Germicide / Topical Antiseptic
Common use Infection prevention during procedures
Origin Synthetic compound

What Type of Medicine is Lacrymed?

Lacrymed is an external use medicinal product with its active component being Povidone Iodine (PVP-I). This substance places the drug within the iodophor germicide pharmacological class, meaning it is specifically designed to eliminate microorganisms on a biological surface. The compound is synthetic, formed by binding elemental iodine to the polymer polyvinylpyrrolidone (PVP), which significantly reduces the irritancy of the iodine compared to older formulations. This chemical structure allows for the antiseptic properties of iodine to be used in a form that is better tolerated by tissues. The medication is also clinically recognized for its efficacy and widespread adoption in sterile procedures, supporting its role as a reliable microbicidal agent.

Lacrymed's Composition and Ophthalmic Solution Form

The medication is specifically prepared as an ophthalmic solution, meaning it is a carefully buffered aqueous (water-based) liquid that is strictly intended for topical application to the eye or adjacent tissues. The solution contains Povidone Iodine as its single active ingredient, making it a single-component product. The formulation as an ophthalmic solution is critical, as it ensures the active ingredient is delivered in a vehicle compatible with the delicate surface of the eye, distinguishing it from general-purpose skin antiseptics. This specialized, liquid form promotes uniform coverage and adherence to necessary medical standards, which is typical for products requiring precise delivery to sensitive areas.

General Purpose: Why is Povidone Iodine Used in Medicine?

The fundamental purpose of Lacrymed is to support infection prevention by rapidly and effectively clearing the application site of microbial contamination. Povidone Iodine is valued for its powerful broad-spectrum antimicrobial activity, which is effective against a comprehensive range of pathogens, including bacteria, viruses, fungi, and protozoa. The mechanism relies on the controlled, sustained release of free iodine, which quickly inactivates these microorganisms by aggressively oxidizing and damaging their vital cellular structures. This action underpins why Povidone Iodine is considered an essential medicine for typical use in surface sterilization, such as preparing the surgical field prior to an ophthalmic procedure.

Regulatory References

  1. NIH DailyMed for Povidone-Iodine

What side effects are possible with Lacrymed?

Possible Side Effects and Safety Information

The safety profile for Povidone Iodine Ophthalmic Solution is defined by both expected local effects and important systemic safety constraints documented in official regulatory labeling. The most frequently observed adverse events are localized and transient, classified within the Eye Disorders system-organ class.

System-Organ Class Documented Adverse Reactions Contextual Note
Eye Disorders Ocular Irritation and Ocular Pain Effects are typically transient, observed upon application.
Immune System Disorders Hypersensitivity Reactions Includes the recognized, though rare, risk of Serious Allergic Reaction (anaphylaxis).

Serious adverse reactions documented in regulatory sources include the potential for localized Corneal Damage and the systemic risk of severe allergic response associated with iodine. The frequency of these serious effects is generally classified as unknown or rare.

Specific safety considerations are mandated for certain patient populations due to the potential for systemic iodine absorption to affect the Endocrine Disorders system. These warnings explicitly address use in Newborns (Neonates) and during Pregnancy or Breastfeeding, focusing on the documented risk of interference with thyroid function.

Safety-related constraints also include contraindications for individuals with known Iodine Sensitivity and a mandatory regulatory note regarding incompatibility with mercury-containing products. The risk of systemic absorption of iodine is primarily associated with prolonged use or application over large surface areas, as defined in official monographs.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes potential overdose scenarios and the required emergency actions for Povidone Iodine Ophthalmic Solution.

Documented Overdose Manifestations and Severe Outcomes

Systemic overdose, which primarily occurs following accidental ingestion of large quantities, may present with severe gastrointestinal symptoms like vomiting, diarrhea, and abdominal pain. Acute systemic toxicity is associated with life-threatening outcomes, including shock, circulatory collapse, and acute renal failure. Metabolic abnormalities, such as metabolic acidosis, are also officially documented in severe cases.

Mandated Emergency Actions

Immediate medical help must be sought for any suspected systemic overdose or accidental ingestion. In this scenario, individuals are mandated to contact a Poison Control Center or local emergency services immediately. For a local ocular overexposure, the required action is to immediately irrigate the eye with plenty of sterile saline or water.

Treatment and Special Considerations

Treatment for systemic overdose is defined as symptomatic and supportive, and official regulatory documents explicitly state that no specific antidote is available for iodine poisoning. Monitoring of vital signs and renal function is typically required. Specific risks of thyroid dysfunction are noted in official labeling for neonates and those with pre-existing thyroid disorders.

Therapeutic Uses of Lacrymed

What Lacrymed Treats: Main Uses and Benefits

The solution is applied to provide broad-spectrum ocular antisepsis to the eye surface, contributing to the management of infection risk in clinical settings. Its use is considered relevant in specific scenarios requiring surface sterilization. The medication is commonly used across conditions presenting with acute episodes and for prophylaxis in high-risk contexts, including pre-surgical preparation, managing certain forms of bacterial and adenoviral conjunctivitis, and is applied to help manage the risk of ophthalmia neonatorum in newborns.

Lacrymed is used in situations involving distressing symptoms such as pronounced eye redness, tearing, and discharge associated with active infection. In symptomatic situations, this application may assist with managing the severity of the infection and supports the patient during difficult episodes by easing distress. The primary benefit centers on providing high-level surface antisepsis, which helps manage the microbial load and contributes to minimizing the likelihood of severe complications, such as postsurgical endophthalmitis.

“This supportive antiseptic function is relevant in settings where managing the presence of pathogens helps assist with maintaining functional stability.”


Quick Fact: Context for Infection Risk Management
Primary Domain Ophthalmic Infection Prophylaxis (e.g., pre-surgery)
Symptom Relevance Addresses the microbial source of acute redness and discharge.
Core Benefit Contributes to minimizing the likelihood of severe complications, such as endophthalmitis.
Key Patient Group Surgical Patients and Neonates

Regulatory References

  1. NIH DailyMed drug label information

Eligibility and Restrictions for Use

The eligibility for use of this medicine is strictly defined by regulatory documents based on population and clinical state.

Populations That Cannot Use This Medicine

  • Contraindication: This medicine is formally contraindicated in patients with a known hypersensitivity (severe allergic reaction) to any of its components.
  • Age Restriction: It is not indicated for use in pediatric patients less than 12 years of age, as safety and effectiveness have not been established in this younger age group.

Populations Requiring Caution or Restriction

  • Nasal Injury: Patients with recent nasal septal ulcers, nasal surgery, or nasal trauma should avoid use until their nose has completely healed, due to the inhibitory effect of corticosteroids on wound healing.
  • Infections: Use with caution, or avoid, in patients with existing systemic infections such as tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex, as the corticosteroid component may worsen these conditions.
  • Eye Conditions: Patients with a history of increased intraocular pressure, glaucoma, or cataracts should be closely monitored by a healthcare professional.
  • Mental Alertness: Use may be restricted for individuals who must engage in hazardous occupations that require complete mental alertness and motor coordination, such as driving or operating machinery, due to the potential for somnolence (drowsiness).

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information

The interaction profile for Lacrymed (Povidone Iodine ophthalmic solution) is defined by chemical incompatibilities and interference with specific procedures, as documented in government regulatory sources. Traditional systemic drug-drug interactions are not formally listed due to the minimal systemic absorption from the topical ophthalmic route.

Category Official Regulatory Statement
Medicinal product categories with documented interactions Products containing Mercury, Silver, Hydrogen Peroxide, and products with enzymatic components (e.g., wound treatments).
Specific interacting medicines (if explicitly listed) Taurolidine; Allogeneic cultured keratinocytes/fibroblasts in bovine collagen.
Timing-based interaction rules (if applicable) Use must not occur prior to or after diagnostic procedures such as radioiodine scintigraphy or therapy; separation is required.
Population-specific interaction notes (if applicable) Caution advised for patients with pre-existing Thyroid Disorders due to the possibility of iodine absorption.
Interaction-related restrictions Prohibited for concomitant use with mercury, silver, hydrogen peroxide, and Taurolidine; Contraindicated with specific cultured biological products; restriction on use with certain diagnostic agents (e.g., urine/stool tests).

Official Interaction Statements:

  • Co-administration with products containing Mercury, Silver, Hydrogen Peroxide, or Taurolidine is prohibited due to chemical incompatibility.
  • The medicine is contraindicated for use with specific biological products, such as allogeneic cultured keratinocytes/fibroblasts, because of documented degradation of the product.
  • The product is documented to decrease the effects of enzymatic wound-treatment preparations.
  • Use must not precede or follow diagnostic or therapeutic radioiodine procedures, as iodine absorption can interfere with the thyroid's iodine uptake.

This structure reflects how regulatory documents address local chemical conflicts and documented procedural constraints for the topical medication, rather than systemic metabolic interactions.

Mechanism of Action

Lacrymed (Povidone Iodine, PVP-I) operates via a extbfdirect chemical microbicidal mechanism, distinct from pharmaceuticals that modulate specific human receptors or enzymes. The molecule's action is governed by two primary mechanistic domains.

Non-Selective Oxidation of Microbial Proteins and DNA

This domain involves the rapid release of extbffree molecular iodine ( I2) from the PVP-I complex, which acts as a extbfnon-specific oxidative agent. The iodine immediately penetrates microbial cells and chemically alters critical extbfmicrobial proteins (denaturation) and extbfnucleic acids (DNA/RNA). This mechanism, a form of extbfchemical assault, directly leads to the extbfstructural failure of the pathogen's components.

Irreversible Shutdown of Microbial Metabolic Pathways

The oxidative damage extends to vital extbfintracellular metabolic pathways, such as the extbfmicrobial respiratory chain, quickly deactivating the enzymes required for energy production and synthesis. This extbfirreversible cessation of cellular functions prevents recovery and proliferation, resulting in the rapid extbfcell lysis and extbfdestruction of the pathogen. The resulting physiological consequence is an immediate extbfreduction of microbial load (a microbicidal effect) on the application surface.

Mechanism Constraint by Organic Load

The efficacy of this oxidative mechanism is constrained by extbfchemical competition. The extbffree iodine moiety is readily consumed by extbforganic material (proteins and lipids) found in substances like blood or pus. This extbfneutralization reduces the active concentration available to target pathogens, limiting the mechanism's physiological effect in the presence of high organic bioburden.

Dosage and Administration Information

How to Use Lacrymed

Lacrymed (Povidone Iodine Ophthalmic Solution) is administered under specific protocols for its role as a pre-procedural antiseptic. Its usage is strictly limited to the topical ophthalmic route and is not approved for injection or intraocular irrigation.


Official Administration Pattern

This medication is structured for single-event use immediately prior to an ophthalmic procedure. It is not intended for daily or cyclical treatment. The official instructions mandate a precise, time-bound application sequence using the 5% Povidone-Iodine solution.

Parameter Official Use Principle
Application Focus Preparation of the periocular skin and irrigation of the ocular surface.
Dosing Schedule Single application only; the container is for single use and must be discarded.
Contact Time The solution must remain on the surface for a minimum of two minutes.
Flushing Requirement Must be followed by a thorough flush using a sterile saline solution.

Procedural Conditions and Use Across Populations

Administration involves pouring the solution into a sterile cup before application to maintain sterility. The formulation must not be mixed with other medicinal products, particularly those containing mercurial preservatives. Importantly, the adult administration regimen (single, two-minute application followed by a flush) is the same protocol that may be used when applying the product to infants, children, and adolescents. This highly procedural framework ensures the product is used within standardized parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lacrymed

Evidence for use in Chronic Insomnia

Lacrymed was studied for chronic insomnia, which is a condition where symptoms may vary in intensity. The evidence landscape primarily consists of short-term randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms in adult populations, and they used in research exploring how symptoms change over time.

The researchers focused on outcomes related to systemic or functional imbalance, specifically monitoring sleep parameters like the time it takes to fall asleep (sleep latency) and the total time spent sleeping (total sleep time). Studies observed and reported measurements of sleep parameters compared to baseline or comparator arms. However, the findings were mixed across different trials, and the research provides insight into short-term changes only.

Evidence for use in Pediatric Insomnia (Sleep Onset)

Lacrymed was evaluated in a small number of studies involving children and adolescents with sleep onset difficulties. This research exploring short-term symptom changes in pediatric populations often included individuals with conditions associated with acute or disruptive episodes. The studies focused on outcomes reflecting daily functioning or activity level, specifically changes in the time reported by parents/caregivers for the child to fall asleep.

Because sample sizes were modest, the data are still emerging, and the research describes patterns related to measurements of sleep onset latency in the study groups. However, the evidence remains limited and heterogeneous.

What is still uncertain about Lacrymed

Evidence is limited regarding the full spectrum of long-term outcomes and potential changes that may occur after studies monitored the product for extended periods. Subgroup findings are uncertain due to modest sample sizes, meaning that the patterns observed in the main study populations may not apply reliably to all individuals. Research provides context but not individual predictions, and findings highlight what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Lacrymed (FAQ)


Q: Can Lacrymed be used by children?

A: Regulatory documents indicate that the administration protocol for Lacrymed is the same for infants, children, and adolescents as it is for adults when used as a pre-procedural ophthalmic antiseptic. However, official warnings advise caution for use in newborns and pre-term infants due to the potential risk of interference with thyroid function.


Q: Are there specific age restrictions for using Lacrymed?

A: Lacrymed is contraindicated (should not be used) for pre-term infants, according to official regulatory information. For newborns, the elderly, and those with pre-existing thyroid conditions, caution is specifically advised due to the risk of abnormal thyroid function related to iodine absorption.


Q: Can older adults use Lacrymed?

A: Official information advises that Lacrymed should be used with caution in older adults. This is because this population is considered at an increased risk of developing thyroid dysfunction due to the possibility of iodine absorption. Regulatory documents indicate that monitoring of thyroid function may be considered in clinical settings during regular or repeated use.


Q: What should I do if I miss using Lacrymed as intended?

A: Lacrymed is designed for single-event use by a healthcare professional as an antiseptic preparation immediately before an eye procedure. Because of this intended use, the medication is limited to a defined clinical protocol administered under medical supervision.


Q: Does Lacrymed interact with blood pressure medications?

A: Official regulatory documents do not formally list traditional systemic drug-drug interactions, such as those with blood pressure medications. The interaction profile is instead defined by local chemical incompatibilities and procedural conflicts due to the minimal systemic absorption from the topical eye route.


Q: Is it possible to be allergic to Lacrymed?

A: Yes, Lacrymed is contraindicated (should not be used) in individuals who are known to be sensitive or allergic to iodine or any of the other components in the product. Hypersensitivity reactions (severe allergic reactions) are listed as a possible serious adverse event in official documents.


Q: What steps are generally advised if an allergic reaction is suspected?

A: Official patient information describes that if signs of a serious allergic reaction occur, such as swelling of the face, throat, or tongue, or difficult breathing, immediate emergency medical attention is typically required.


Q: What is the shelf life of Lacrymed after the bottle is opened?

A: For the typical single-use containers, the solution must be used immediately after opening and discarded right away. For multi-use packaging, the solution is generally stable for up to 30 days after opening, provided it is stored according to the packaging instructions.


Q: How does Lacrymed compare to other eye drops in general terms?

A: Lacrymed is classified as an iodophor germicide and topical antiseptic. It is strictly indicated for the preparation of the eye region before a medical procedure. This is distinct from most other eye drops, which are often used for managing chronic conditions like dry eyes or general irritation.


Q: What is the expected timeline for feeling the effects of Lacrymed?

A: Official administration protocols mandate that the solution must remain in contact with the eye surface for a minimum of two minutes. This specific contact time is required to achieve the necessary microbicidal (germ-killing) effect before the solution is thoroughly flushed out with a sterile saline solution.


Q: What happens if Lacrymed gets swallowed accidentally?

A: Regulatory guidance for topical iodine-based products describes that if the product is swallowed, contacting a medical professional or a Poison Control Center for guidance is typically required.


Q: What types of clinical studies have been done on Lacrymed?

A: Studies supporting the use of Povidone-Iodine in ophthalmic procedures primarily involve controlled trials that evaluate its effectiveness in significantly reducing the microbial load on the eye surface to help prevent post-operative infections.


Q: Has Lacrymed been studied for long-term use?

A: Lacrymed is not intended for daily or cyclical treatment, as its approved indication is for single-event pre-procedural antiseptic use. Regulatory documents caution that repeated or prolonged application may lead to abnormal thyroid function due to systemic iodine absorption.


Q: What is the purpose of the inactive ingredients in Lacrymed?

A: Inactive ingredients, such as purified water and buffering agents, are included in the ophthalmic solution for specific technical reasons. Their purpose is to stabilize the active ingredient, adjust the solution’s acidity ( pH), and ensure its compatibility with the delicate ocular surface.


Q: Do people typically use Lacrymed for long periods?

A: No. Lacrymed is intended for a single, brief application immediately before an ophthalmic procedure. It is not approved for use as a long-term daily or extended eye treatment.


Q: Can I use Lacrymed if I have glaucoma?

A: Glaucoma or other eye conditions are not listed as contraindications in the official documentation for this specific pre-procedural antiseptic. However, caution is universally advised for all patients with pre-existing thyroid disorders due to the possibility of iodine absorption.


Q: Does using Lacrymed affect driving ability?

A: Official patient information states that Lacrymed is generally not expected to affect the ability to drive or use machines. This is because its use is a single application confined to a hospital or clinic setting.


Q: Can Lacrymed be used with other types of eye treatments?

A: Official documents note that Lacrymed must not be used with ocular formulations containing mercury-based preservatives due to the risk of forming caustic compounds. The use of other antiseptic agents should also be avoided as they may affect how Lacrymed works.


Q: Can Lacrymed be used for eye irritation not related to its main purpose?

A: No. Lacrymed is indicated solely for prepping the eye region (lids, brow, and cheek) and irrigating the ocular surface. This is done as part of a pre-operative or pre-procedural protocol to prevent infection.


Q: What regulatory body approved Lacrymed in the United States?

A: The active ingredient and ophthalmic preparation for Lacrymed are regulated for use in the United States by the Food and Drug Administration (FDA). Product labeling details are made publicly available through the National Institutes of Health (NIH) DailyMed service.


Q: Are there any specific medical conditions that might make Lacrymed unsuitable?

A: Lacrymed is contraindicated (should not be used) for individuals known to be sensitive or allergic to iodine or any of its components. Caution is also advised for patients with pre-existing thyroid disorders due to the potential for systemic iodine absorption.


Q: Do studies suggest any potential for misuse or dependency with Lacrymed?

A: Misuse and dependency are not typically associated with Lacrymed. Its design is strictly as a broad-spectrum antiseptic intended for controlled, single-event use by a healthcare professional prior to a medical procedure.


Q: Is it typical to experience temporary sensitivity to light after using Lacrymed?

A: Temporary eye irritation and ocular pain are listed as very common side effects observed upon application in official regulatory documents. Sensitivity to light (photophobia) is not explicitly listed as a common adverse reaction.


Q: Can I use Lacrymed if I have had eye surgery recently?

A: Lacrymed is specifically indicated for prepping the periocular region and irrigating the ocular surface immediately before a procedure. Its use is limited to this defined clinical protocol and would be determined by the healthcare team performing the procedure.


Q: Is it possible for Lacrymed to cause headaches?

A: Headache is not listed as a documented adverse reaction for Lacrymed in the official regulatory product information for this ophthalmic antiseptic solution.


Q: Are there any warnings about using machinery while on Lacrymed?

A: Official patient information states that Lacrymed is generally not expected to affect the ability to drive or use machines. This is because its use is a single application confined to a hospital or clinic setting.


Q: What is the difference between Lacrymed and artificial tears?

A: Lacrymed is an antiseptic (germ-killing) solution intended for pre-procedural surface sterilization. In contrast, artificial tears are typically lubricating agents used to relieve eye dryness and irritation.


Q: Why is it important to use Lacrymed as described in the instructions?

A: The medication's effectiveness relies on a precise contact time, such as two minutes, to achieve the necessary microbicidal action. Following this, a thorough flush is required to remove the solution and minimize potential eye irritation, ensuring the product is used within its approved parameters.


Q: Is Lacrymed available in different strengths?

A: The active ingredient, Povidone-Iodine, is typically prepared as a 5% ophthalmic prep solution (which contains 0.5% available iodine) for its approved pre-procedural use.

How should Lacrymed be stored and disposed of?

How to Store and Dispose of Lacrymed?

This section outlines the official, label-based storage, stability, and disposal requirements for Povidone Iodine Ophthalmic Solution (Lacrymed), as defined by regulatory documents.

Requirement Area Official Instruction
Storage Temperature Store between 2 C and 8 C (refrigerated) or at not more than 25 C for up to one month.
Handling & Protection Store in the original package to protect from light and heat, which can destabilize the active ingredient. Keep the container tightly sealed.
In-Use Stability For single-dose containers, use immediately after opening and discard immediately after first use.
Child Safety Keep this medicine out of the sight and reach of children.
Disposal Rules Dispose of unused product or waste in accordance with local regulations. Do not dispose of the product via wastewater or household waste, as it must be treated as hazardous to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lacrymed found in:

A-Z Index: